Preface

The “Current Cancer Therapy Reviews” (CCTR) will now publish its 17th volume. I have been the editor-in-chief of CCTR for over a year. I want to thank all the contributors, past and present, for making CCTR a relevant journal for researchers in the field of pharmacology and oncology. I also welcome our current and new readers as well as researchers to CCTR and encourage them to bring new insights to the expanding body of information on the subject.

The year 2020 was overshadowed by the COVID-19 pandemic, which had a significant impact on the lives of many people, including researchers, around the world. The good news is that many teams have already developed vaccine candidates, some of which show high efficacy rates (in excess of 90%). I hope 2021 allows us to be a part of a stronger fight against this pandemic. While I initially hoped to publish 4 issues in the previous year, this was not possible to achieve; however, CCTR’s editorial board members, reviewers, and publishing staff have worked hard throughout this time to keep the journal on schedule, and their efforts are very much appreciated. For this year, our goal is to continue to publish high-quality articles and publish more research articles this year.

This year’s first issue brings forth 6 articles on cancer therapy: 4 reviews and 2 research articles. The reviews cover general methods of cancer therapy (through the use of functionalized liposomes and bacterial superantigens) and cancer therapy for gliomas and insulin-mediated metastatic breast cancer.

The first of the research articles documents different gene polymorphisms that can be used to predict the incidence of hepatocellular carcinoma following a hepatitis B infection. The study led by Sherief Abd-Elsalam of Tanta university has been conducted on Egyptian patients and suggested that Human Leukocyte Antigen (HLA) DQ alleles can also be used as predictors for hepatocellular carcinoma in this region. The second research article is the first report on the anti-cancer effect of Paris polyphylla Smith in SAS Oral cancer cell lines. We hope to bring more new contributions to cancer therapy research this year like these.

Once again, I am grateful to authors, reviewers, and the Bentham Science staff for assisting in the publication of the new CCTR volume.

Prof. Yangchao Chen
(Editor-in-Chief)
School of Biomedical Sciences
Faculty of Medicine
The Chinese University of Hong Kong
Shatin
Hong Kong
E-mail: yangchaochen@cuhk.edu.hk